A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats

Journal of the American College of Cardiology

Volumn 40, Issue 1, 2002, Pages 175-181

  Ueno, Michihiko ^a   Miyauchi, Takashi ^a   Sakai, Satoshi ^a   Yamauchi Kohno, Rikako ^b   Goto, Katsutoshi ^a   Yamaguchi, Iwao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; ENDOTHELIN A RECEPTOR ANTAGONIST; MESSENGER RNA; MONOCROTALINE; MYOSIN HEAVY CHAIN; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; PROSTACYCLIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; THICKNESS; TREATMENT OUTCOME;

EID: 0037014650     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01911-3     Document Type: Article

References (36)

1. Recognition and management of pulmonary hypertension
2. Primary pulmonary hypertension: Natural history and the importance of thrombosis
3. The effect of high dose of calcium-channel blockers on survival in primary pulmonary hypertension
4. A comparison of continuous intravenous epoprostenol (prostacycLin) with conventional therapy for primary pulmonary hypertension
5. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension
6. The role of endothelium in cardiovascular homeostasis and diseases
7. An imbalance between the excretion of thromboxane and prostacycLin metabolite in pulmonary hypertension
8. 1 for severe idiopathic pulmonary artery hypertension
9. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
10. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
11. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
12. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension
13. 2 analogue, beraprost, in primary and secondary pulmonary hypertension
14. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species
15. 2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension: A case report
16. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
17. Pathophysiology of endothelin in cardiovascular system
18. Heart failure and endothelin receptor antagonists
19. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
20. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-like immunoreactivity in the lung in congestive heart failure in rats
21. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair
22. Contribution of endogenous endotheiln-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
23. Contribution of endogenous endothelin-1 to the progression of right-sided heart failure caused by pulmonary hypertension in rats: Improvement of survival and of failing right ventricular gene expression by chronic treatment
24. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
25. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
26. Distribution of endothelin-1 in the lung of rats with pulmonary hypertension of different etiology
27. Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors
28. Changes in pulmonary structure and function induced by monocrotaline intoxication
29. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist
30. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothlin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function
31. Echocardiographic evaluation of pulmonary hypertension
32. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure
33. 2, and prostacyclin
34. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial ceils
35. Inhibition of endothelin-1-induced DNA synthesis by prostacyclin and its stable analogues in vascular smooth muscle cells
36. The role of thrombosis in severe pulmonary hypertension